IOM. Research Strategies for Assessing Adverse Events Associated with Vaccines: A Workshop Summary. Washington, D.C.: National Academy Press, 1994c.
IOM. Options for Poliomyelitis Vaccination in the United States: Workshop Summary. Washington, D.C.: National Academy Press, 1996.
Janoff EN, et al. Increased HIV-1 burden with immune activation following immunization with pneumococcal vaccine. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, (Abstract No. 1237). Washington, D.C.: American Society of Microbiology, 1995.
Lasky T, Terracciano G, Chen R, et al. The association of GBS with the influenza vaccines of 1992–1993 and 1993–1994. Presentation to the Advisory Committee on Immunization Practices, February 12, 1997, Atlanta.
Martin WJ, Ahmed KN, Zeng LC, Olsen JC, Seward JG, Seehrai JS. African green monkey origin of the atypical cytopathic ''stealth virus" isolated from a patient with chronic fatigue syndrome. Clinical and Diagnostic Virology 1995; 4:93–103.
Martin WJ, Zeng LC, Ahmed K, Roy M. Cytomegalovirus-related sequence in an atypical cytopathic virus repeatedly isolated from a patient with chronic fatigue syndrome. American Journal of Pathology 1994; 145:440–451.
O'Brien WA, et al. HIV-type 1 replication can be increased in peripheral blood of seropositive patients after influence vaccination. Blood 1995; 86:1082–1089.
Rosenthal S, Chen RT. Reporting sensitivities of two passive surveillance systems for adverse events. American Journal of Public Health 1995; 85:1706–1709.
Tasker S, et al. Effects of influenza vaccination in HIV infected patients: A double blinded placebo controlled trial. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, (Abstract No. LB-11). Washington, D.C.: American Society of Microbiology, 1995.
Wise RP. Medical review of vaccine safety reports. Presentation to the Vaccines and Related Biological Products Advisory Committee, August 24, 1994.